Moreover, the combined treatment with anti-PD-1 and DIM could increase the percentage of CD4+ and CD8+ T cells in spleen, blood and tumor tissue compared with the single treatment group (Fig. 4F and Additional file 1: Fig. S1F). The gene discussed is CD8A; the disease is neoplasm.